Uremic phase of chronic kidney disease
Conditions
Interventions
Propofol group:The maintenance of anesthesia was performed with propofol
Rimazole group:The maintenance of anesthesia was performed with rimazole
Sponsors
The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfo Mountain hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Voluntarily sign the informed consent form; (2) Age between 18 and under 65 years; (3) Patients with chronic renal failure undergoing renal transplantation; (4) Body mass index (BMI): 18~30kg/m^2 (including boundary value), no less than 50kg for male patients and no less than 45kg for female patients; (5) ASA grade: II~III.
Exclusion criteria
Exclusion criteria: (1) Patients with liver, mental, nervous system diseases, coagulation dysfunction, heart failure, respiratory failure, long-term use of sedatives or antidepressants; (2) Pregnant or lactating women and patients who cannot communicate or cooperate; (3) Patients who participated in the trial of drugs or medical devices within 3 months before the trial; (4) Hepatitis B surface antigen, hepatitis C antibody, HIV antibody or syphilis antibody positive; (5) Any drug that inhibits or induces hepatic drug metabolizing enzymes within 30 days before screening (see Appendix 1 for details); (6) Allergic constitution, such as those with known history of allergy to two or more substances; (7) Heavy drinking or regular drinking within 6 months before screening, i.e. drinking more than 14 units of alcohol per week (1 unit =360 ml beer or 45 ml alcohol 40% spirits or 150 ml wine); (8) Those who had a history of drug abuse and drug abuse 3 months before screening; (9) Patients with serious infection, trauma, major surgical operation, digestive system surgery affecting drug absorption within 1 month before screening; (10) Those who had been vaccinated within 1 month before screening or planned to be vaccinated within the trial period; (11) Those who had lost blood or donated blood > 400 ml within 3 months before screening, or received blood transfusion within 1 month; (12) Abnormal coagulation function (inr>1.5 or prothrombin time (PT) >uln+4 seconds or aptt >15 × ULN), or significant clinical bleeding symptoms or definite bleeding tendency within 3 months before screening, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, etc., or receiving thrombolytic anticoagulant therapy; (13) The researcher believes that the study participants have any factors that are not suitable to participate in this trial;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Qor-15 score 24 hours after operation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Qor-15 score 48 hours after operation;Hemodynamic stability;Postoperative cognitive function;Postoperative emotional state;Postoperative anxiety and depression;Incidence of postoperative shivering;Postoperative recovery of renal function; | — |
Countries
China
Contacts
Public ContactWu Jianbo
The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfo Mountain hospital)
Outcome results
None listed